NCT02451514View on ClinicalTrials.gov

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 14, 2015

Study Completion Date

December 10, 2015

Conditions
Meningococcal DiseaseInfections, Meningococcal
Interventions
BIOLOGICAL

MenABCWY+OMV vaccine

Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.

Trial Locations (7)

110221

GSK Investigational Site, Bogotá

8860000

GSK Investigational Site, Santiago

Unknown

GSK Investigational Site, Bogotá

GSK Investigational Site, Panama City

081600383

GSK Investigational Site, Panama City

0834 00363

GSK Investigational Site, Panama City

0843 01103

GSK Investigational Site, Panama City

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02451514 - A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) | Biotech Hunter | Biotech Hunter